A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Small intestinal submucosa === Small intestinal submucosa (SIS) is submucosal tissue in the small intestines of vertebrates. SIS is harvested (typically from pigs) for transplanted structural material in several clinical applications, typically biologic meshes. They have low immunogenicity. Some uses under investigation include a scaffold for intervertebral disc regeneration. Unlike other scaffold materials, the resorbable SIS extracellular matrix (SIS-ECM) scaffold is replaced by well-organized host tissues, including differentiated skeletal muscle.
Many covalent binary nitrides are known. Examples include cyanogen ((CN)2), triphosphorus pentanitride (P3N5), disulfur dinitride (S2N2), and tetrasulfur tetranitride (S4N4). The essentially covalent silicon nitride (Si3N4) and germanium nitride (Ge3N4) are also known: silicon nitride, in particular, would make a promising ceramic if not for the difficulty of working with and sintering it. In particular, the group 13 nitrides, most of which are promising semiconductors, are isoelectronic with graphite, diamond, and silicon carbide and have similar structures: their bonding changes from covalent to partially ionic to metallic as the group is descended. In particular, since the B–N unit is isoelectronic to C–C, and carbon is essentially intermediate in size between boron and nitrogen, much of organic chemistry finds an echo in boron–nitrogen chemistry, such as in borazine ("inorganic benzene"). Nevertheless, the analogy is not exact due to the ease of nucleophilic attack at boron due to its deficiency in electrons, which is not possible in a wholly carbon-containing ring. The largest category of nitrides are the interstitial nitrides of formulae MN, M2N, and M4N (although variable composition is perfectly possible), where the small nitrogen atoms are positioned in the gaps in a metallic cubic or hexagonal close-packed lattice. They are opaque, very hard, and chemically inert, melting only at very high temperatures (generally over 2500 °C). They have a metallic lustre and conduct electricity as do metals. They hydrolyse only very slowly to give ammonia or nitrogen.
The Inter-American Conference of Symbolic Masonry was an international gathering of Freemasons from around the world for the member Grand Lodges and Orients of the Inter-American Masonic Confederation (CMI). The First Inter-American Conference of Symbolic Masonry was hosted in Montevideo in 1947. The second was hosted in Mexico City in 1951. The third was held in Havana. From February 25 to March 8, 1955, Freemasonic delegations from Europe, Asia, and America (e.g.; North America and South America), and their families, landed at Havana to participate in the Third Inter-American Conference of Symbolic Freemasonry. When the delegations arrived at Havana Airport on Friday the 25th, at different prearranged times, they were greeted by the Cuban Marine Corps Band which marched onto the airfield and played the national anthems of the delegations, before they were brought to their hotel for the conference, the Sevilla Biltmore. That night, the delegations were given time to become acquainted with the city of Havana. The delegation from the United States enjoyed an evening at the Tropicana.
Sources: en.wikipedia.org
At a time of increasing cooperation between the Western Allies and the Soviet Union in the wake of the Nazi invasion of 1941, the influence of the Polish government-in-exile was seriously diminished by the death of Prime Minister Władysław Sikorski, its most capable leader, in a plane crash on 4 July 1943. Around that time, Polish-communist civilian and military organizations opposed to the government, led by Wanda Wasilewska and supported by Stalin, were formed in the Soviet Union. In July 1944, the Soviet Red Army and Soviet-controlled Polish People's Army entered the territory of future postwar Poland. In protracted fighting in 1944 and 1945, the Soviets and their Polish allies defeated and expelled the German army from Poland at a cost of over 600,000 Soviet soldiers lost.
and hit .409 with 11 home runs, 20 walks and 1.384 OPS and collected his second consecutive Player of the Month award. He would hit another three home runs with six walks in nine August games before a pitch from Andy Benes fractured his left hand on August 10 and ended his season in the same manner the season before. Entering that game, Bagwell carried an 18-game hitting streak. Two days later, the strike ended the season for all the major leagues. His production accelerated in 26 games after the All-Star break, as he posted a .432 batting average, .530 OBP, .916 SLG, 1.446 OPS, 10 doubles, 12 home runs, 34 RBI and 30 runs scored. The Astros finished one-half game out of first place in the inaugural season of the National League Central division, a product of MLB's division realignment. Bagwell played in 110 games in the 1994 season, batting .368 with a .750 SLG, 1.201 OPS, 39 home runs, 116 RBI, 104 runs scored, 300 total bases and 213 adjusted OPS (OPS+) in 400 at bats. He led the major leagues in SLG, OPS+, RBI, and total bases, and the NL in runs scored and OPS, but fell short of winning the batting Triple Crown, finishing second for the batting title to Tony Gwynn, who, after batting .394, had the highest average in the major leagues since Ted Williams in 1941. Bagwell finished second in home runs to Matt Williams, who hit 43.
May 13–15 – President Trump makes a state visit to China and meets with Chinese leader Xi Jinping. May 13 – The U.S. Senate confirms Kevin Warsh as the Chair of the Federal Reserve in a 54–45 vote. Warsh will succeed Jerome Powell at the end of the latter's term. May 14 Federal employees sue USDA and Secretary Brooke Rollins on First Amendment grounds over proselytizing Christian messaging in work emails. Mike Banks resigns as U.S. Border Patrol Chief, saying he wanted to spend time with family. Bank's resignation came weeks after the Washington Examiner alleged that he engaged in sex tourism in Colombia and Thailand. May 16 – 2026 Long Island Rail Road strike: Five unions representing over 3,500 workers for the Long Island Rail Road, the largest commuter rail system in North America, go on strike to negotiate a new contract with the Metropolitan Transportation Authority in New York City. May 18 – Five people, including two gunmen, are killed in a mass shooting at a mosque in San Diego, California. May 18–19 – The DOJ announces they reached a settlement with the Internal Revenue Service to resolve Trump's $10 billion lawsuit regarding the 2020 leak of his tax returns to The New York Times. Trump drops the lawsuit but will receive a $1.776 billion "anti-weaponization fund" to give to people who were prosecuted by the Biden administration. A day later, the DOJ reveals that the settlement terms include that the IRS is "forever barred and precluded" from investigating past tax returns filed by President Trump, his family and his businesses. May 19 – U.S.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.